ABSTRACT The activity of phospholipase inhibitory protein, lipomodulin, partially purified from rabbit neutrophils, was markedly decreased after treatment with sera from patients with rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis, and dermatomyositis. The decrease of the protein's inhibitory activity on phospholipase A2 paralleled the amount of [35S]methionine-labeled lipomodulin precipitated by the sera. Absorption ofpatients' sera with anti-human IgM (,u chain) or protein A-agarose, but not with anti-human IgG (ychain), decreased their ability to decrease. the activity of lipomodulin on phospholipase A2 or to precipitate the radioactive li omodulin. The IgM fraction of patients' sera could precipitate [ S]methionine-labeled lipomodulin (40,000 daltons) which comigrated with highly purified Iipomodulin on gel electrophoresis with sodium dodecyl sulfate. All of these observations suggest that the sera of many patients with rheumatic diseases contain autoantibody against lipomodulin. A monoclonal antibody against lipomodulin was also obtained. Stimulating human fibroblasts with bradykinin in the presence of monoclonal antilipomodulin antibody markedly enhanced arachidonic acid release due to the activation of phospholipase(s) in the intact cells, and this stimulatory effect was blocked by adding purified lipomodulin. These findings suggest that lipomodulin regulates the activity of phospholipase(s) on the cell surface and that autoantibodies against lipomodulin may play a role in certain symptoms of rheumatic diseases, especially by the formation of prostaglandins and other metabolites of arachidonic acid.
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A phospholipase A2 inhibitory protein, which we propose to name "lipomodulin," was recently isolated from neutrophils treated with glucocorticoids (1). This protein was found to inhibit phospholipase A2 (phosphatide 2-acylhydrolase, EC 3.1.1.4), an enzyme that cleaves the ester bond in the A3-position of phosphatidylcholine, to liberate unsaturated fatty acids (mainly arachidonic acid) and lysophosphatidylcholine. Lipomodulin was shown to be induced by glucocorticoids in a receptor-mediated fashion (1) . The inhibitory action of glucocorticoids on prostaglandin formation has been assumed to be due to induction of this inhibitory protein, which decreases the availability of the precursor ofprostaglandins, arachidonic acid, by inhibiting phospholipase A2 (1, 2) .
Recently, autoantibodies for cell surface molecules have been detected in patients with myasthenia gravis, Graves disease, insulin-resistant diabetes, or asthma (3) (4) (5) (6) . These antibodies are assumed to be closely related to the pathogenesis of the symptoms that these diseases produce. Because prostaglandins and hydroxyl compounds of arachidonic acid are thought to play a role in the pathophysiology of rheumatic diseases (7), we initiated a search for autoantibodies against lipomodulin.
We report here the presence of autoantibodies against lipomodulin, a cell surface protein, in the sera of many patients with rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis, chronic inflammatory diseases.
EXPERIMENTAL PROCEDURES Purification and Assay of Lipomodulin. Lipomodulin was purified, by a procedure to be described elsewhere, from 400 ml of medium (RPMI-1640) [5,6,8,9,11,12,14, 15- The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
washed twice with 1 ml of Dulbecco's medium, and incubated for 15 min at 37TC in 1 ml of the same medium with or without lipomodulin and other additions as indicated. Bradykinin was then added (final concentration, 0.5 Ag/ml) and, after 30 min at 37TC, the incubation was stopped by adding 0.5 ml of 6 M formic acid. A 1-ml sample ofmedium was centrifuged at 27,000 X g for 25 min, and 0.5 ml of the supernatant was used to measure [3H]arachidonate and its metabolites.
Lipomodulin Antibodies. A monoclonal antilipomodulin antibody was identified among antibodies raised against rat cerebral cortical synaptic plasma membranes (8) . Splenic lymphocytes from immunized BALB/c mice were fused with mouse myeloma cells (P3X63Ag8) to yield hybridomas producing monoclonal antibodies. Among 44 monoclonal antibodies studied, one, designated 44C3, prevented lipomodulin's inhibition ofphospholipase A2 in vitro. The isolation and characterization of the antibodies will be described in detail elsewhere.
Clotted blood from healthy subjects or patients diagnosed as having rheumatic diseases (e.g., systemic lupus erythematosus) was centrifuged at 1600 x g for 10 min. Some sera were separated into IgM and IgG fractions by column chromatography on Bio-Gel A-200. Sera from MRL/l and NZB (NZB x NZW)FI mice were obtained as described (9) .
Rabbit anti-mouse IgG (heavy and light chains) and anti-human IgG (heavy and light chains) were purchased from Miles. Rabbit anti-human IgM (, chain) and anti-human IgG (y chain) were from Boehringer Mannheim.
For the experiments shown in Figs. 2 and 3, samples of lipomodulin (2-3 ,ug) were preincubated at 37TC for 30 min with samples of serum from patients with rheumatic diseases in a total volume of 26 ,u containing 0.1% Trasylol (a protease inhibitor) and 25 mM Tris HCI buffer (pH 7.0). Anti-human IgG (light and heavy chains) (4 ,ul) was added, and the incubation was continued for another 30 min. The tubes were centrifuged in a Beckman Microfuge B for 2 min and an aliquot (10 ,u) of the supernatant was used for the lipomodulin assay described above (assay I). When [3S]methionine-labeled lipomodulin was used, the volume ofthe mixture was doubled and the precipitate was washed twice with 0.5 ml of 150 mM NaCVlO mM sodium phosphate, pH 7.4. The immunoprecipitates were dissolved in 100 ,Al of1% sodium dodecyl sulfate/10 mM sodium phosphate, pH 7.0/0.1% 2-mercaptoethanol. A sample (50 ,ul) was used for radioassay and the remaining 50 ,ul was subjected to gel electrophoresis as described (10 (Fig.  1) . The activity of phospholipase A2 was inhibited by lipomodulin in a dose-dependent manner. After pretreatment of lipomodulin with monoclonal antibody, the dose-response curve was shifted to the right. At a fixed concentration oflipomodulin, increasing amounts of monoclonal antibody resulted in a decrease in lipomodulin activity. All ofthese data suggest that this monoclonal antibody is specific for lipomodulin. It should be noted that, without the precipitation by the second antibody, the soluble monoclonal antibody-lipomodulin complex could inhibit phospholipase A2 activity in vitro, suggesting that the monoclonal antibody and the phospholipase interact with different domains of lipomodulin.
Activation of Phospholipase(s) in Fibroblasts by Monoclonal Antibody. Fibroblasts release arachidonic acid and its metabolites in response to proteins and peptides such as bradykinin (11) . When human fibroblasts were treated with the monoclonal antibody, the basal level of arachidonate release was slightly increased (Table 1 ). In the presence ofbradykinin, the antibody increased arachidonate release 2-to 3-fold. Lipomodulin inhibited the bradykinin-induced arachidonate release from fibroblasts but had no effect on the basal release. These results suggest that lipomodulin is involved in the regulation of phospholipase(s) activity by bradykinin and that the monoclonal antibody enhances the stimulatory effect of bradykinin by interacting with lipomodulin on the surface of the cells. This was further supported by the observation that, when purified lipomodulin was added together with the antibody, the arachidonate release stimulated by bradykinin was almost completely lupus erythematosus (9, 13), all had varying amounts of antilipomodulin antibodies in their sera. To differentiate antilipomodulin antibody from antibodies against IgG or DNA which are also increased in rheumatic diseases (13) , positive sera were incubated with an excess ofheat-denatured calf thymus DNA and heat-denatured human gamma globulins for 1 hr at 37°C and 48 hr at 4°C, respectively, after which the supernatant was examined for antilipomodulin activity. Although all anti-DNA and all anti-gamma globulin activities were removed, the antilipomodulin activity remained. A positive serum from a patient with systemic lupus erythematosus was treated with various anti-human immunoglobulins and their effects on lipomodulin were measured. Anti-human IgM (,u chain) and protein A-agarose but not anti-human IgG (y chain) bound and removed the antibody activity against lipomodulin (Table 3) . Essentially similar results were obtained with seven patients. Neither the patient's serum nor rabbit antihuman IgG activated or inhibited the phospholipase A2 activity in the assay system. The data suggested that patients with rheumatic diseases have IgM autoantibody against lipomodulin. Consistent with this interpretation was the observation that the IgM fraction, but not the IgG fraction, from a positive serum removed lipomodulin activity.
Identification of Lipomodulin Precipitated by Monoclonal Antibody and Serum from Rheumatic Patients. Incubation of [3S]methionine-labeled lipomodulin with serum from a patient with systemic lupus erythematosus followed by the addition of anti-human IgG (heavy and light chains) led to precipitation of radioactivity in amounts dependent on the volume ofthe serum added (Fig. 2 Left) . Serum from a normal subject did not precipitate any radioactive material. The radioactivity in the immunoprecipitates paralleled the decrease in lipomodulin activity in the supernatant (Fig. 2 Right) . To A2 and whose synthesis is induced by glucocorticoids (1, 2) . Phospholipase A2 has been recognized as an important enzyme in the release of prostaglandin precursors, especially arachidonic acid, although recent work with platelets implicated a phosphatidylinositol-specific phospholipase C that yields diacylglycerol and, subsequently, arachidonic acid (7). The present report demonstrates that a substantial proportion of patients with one of four different rheumatic diseases spontaneously produce antibodies against lipomodulin. These antibodies interfere with lipomodulin's inhibition of arachidonic acid release. Thus, in such patients, the antilipomodulin antibody increases the formation of arachidonic acid and, subsequently, the formation of inflammatory prostaglandins. This concept is supported by the observation that inhibitors ofprostaglandin synthesis such as chloroquines and glucocorticoids are effective therapeutically in such patients (13, 14) . In addition, the present experiments showed that anti-lipomodulin antibody present in sera of patients with systemic lupus erythematosus potentiated the stimulatory activity ofbradykinin on the release ofarachidonic acid, whereas purified lipomodulin overcame this effect.
Rheumatic arthritis and systemic lupus erythematosus are diseases ofchronic inflammation. Prostaglandins appear to play an important role in chronic inflammation in these diseases as well as altering lymphocyte function (13, 14) . It was added to these reaction mixtures and incubation at 40C was continued 24 hr. After centrifugation, the immunoprecipitates were washed and subjected to electrophoresis. The gels were sliced from the bottom to the front (marker dye, bromophenol blue). Ela mune diseases is further supported by the finding of such antibodies in the sera ofNZB and MRL/l mice, models ofsystemic lupus erythematosus. The detection of antilipomodulin antibody in only half of the patients with rheumatic diseases might be due to lack of sensitivity of the assay we used. Alternatively, such antibodies may be important in some, but not all, patients. In those patients with antibody, however, the titer of antibody correlated with the severity of the disease. In addition, among patients studied only once, those in the active phase of disease had considerably higher titers than did inactive patients.
The antibody nature ofthe lipomodulin-binding proteins was demonstrated by specific interaction with antibodies against human immunoglobulins. The greater part of the antibody activity was found in the IgM fraction, and anti-IgM antibody specifically depleted the relevant antilipomodulin activity. These results are consistent with the large number of autoantibodies produced by patients with various autoimmune diseases. Moreover, adsorption experiments clearly demonstrated that the antilipomodulin antibodies were distinct from antibodies against DNA and human gamma globulins. Thus, the major autoantibodies produced by patients with systemic lupus erythematosus or rheumatoid arthritis could not be implicated by crossreactivity. It appears that the antibodies against lipomodulin may represent a new autoantibody type in these patients.
Preliminary experiments have suggested that the antilipomodulin antibody favors IgE-potentiating factor synthesis whereas lipomodulin favors IgE-suppressive factor production. IgE-potentiating factor(s) was also induced upon the incubation of rat lymphocytes with melittin, phospholipase A2 activator, or lysophosphatidylcholine or its analogues (unpublished data). These results are consistent with the reciprocal effects of antilipomodulin antibody and glucocorticoids on phospholipase activation. Thus, in addition to its potential role in augmenting inflammation, antilipomodulin antibody might bring about an apparent deficiency in suppressor function (13, 14) . Although the antibodies against lipomodulin could play a role in both inflammatory and lymphocyte abnormalities in patients with rheumatic diseases, the discovery of these antibodies does not yet shed light upon the pathogenesis ofthese disorders. Nevertheless, understanding the mechanisms of induction of inflammation in these disorders should lead to better approaches to therapy.
